[Translation] SHENNONG: A real-world, prospective, observational study evaluating the efficacy of evolocumab plus standard therapy versus standard therapy alone on major cardiovascular events in Chinese patients with established atherosclerotic cardiovascular disease
根据当地临床实践,在应用标准治疗(SOC)确诊为ASCVD的患者中进行一项疗效对比研究,旨在评估依洛尤单抗联合标准治疗(SOC)与单用标准治疗相比,对CV死亡、MI、卒中、因不稳定型心绞痛住院治疗或冠状血管重建等风险的真实世界疗效,以先发生者为准。
[Translation] Methods: A comparative efficacy study was conducted in patients with ASCVD diagnosed with standard of care (SOC) according to local clinical practice to evaluate the real-world efficacy of evolocumab combined with SOC compared with SOC alone on the risk of CV death, MI, stroke, hospitalization for unstable angina, or coronary revascularization, whichever occurred first.